V ein of Galen aneurysmal malformations (VGAMs) are rare congenital abnormalities (less than 1/25 000 deliveries), which can cause severe morbidity and mortality, particularly in neonates but also in infants and older children. [1] [2] [3] [4] [5] They present in several different ways in childhood, the most striking being as high output cardiac failure in the newborn period. 6 In the past, this was usually associated with rapid progression to multisystem organ failure (MOF) and death, despite vigorous treatment and supportive medical care. 7 In the past decade, endovascular treatment has emerged as the treatment of choice for VGAM presenting in infancy with heart failure. Embolisation, both of feeding arteries and draining veins, can result in considerable reduction in aneurysmal blood flow, and has produced encouraging results in selected infants with VGAM. 1 8 9 To date, however, endovascular treatment has been generally used on a selective basis in infants with VGAM, and in many series, neonates less than 1 month of age have not been treated because of perceived poor outcome. Lasjaunias and ter Brugge 10 have proposed a scoring system to select those neonates with cardiac failure that may gain most benefit from endovascular treatment. This scoring system is based on an assessment of MOF associated with the high output state. These investigators maintain that VGAM related cardiac failure in the neonatal period with MOF is associated with a high rate of cerebral infarction, and thus poor prognosis for long term neurodevelopmental outcome. 11 12 Modern neonatal intensive care, neuroanaesthesia, and endovascular treatments have the potential to improve survival and minimise subsequent morbidity in this group. Our unit's philosophy is therefore that urgent endovascular and aggressive medical treatment of cardiac failure should be instituted as soon after diagnosis as possible. A review was undertaken of the clinical features, investigations, and medical management of neonates with VGAM related cardiac failure referred to our institution over the past five years. Our purpose was fourfold: (1) to highlight the important aspects of assessment and stabilisation before embolisation, as well as the medical management during embolisation; (2) to elucidate the most consistently useful treatments of cardiac failure; (3) to document the hospital course and complications in neonates with VGAMs; (4) to review the long term outcome of VGAMs presenting with intractable heart failure in the newborn period, and examine whether the severity of neonatal cardiac failure or the presence of MOF are predictors of neurodevelopmental outcome.
This group has also examined the timing and nature of the embolisation procedures performed in infants with VGAMs over the same time period. This review is the subject of a separate report, which complements the data presented here. 13 
METHODS
All neonates, treated at the Royal Children's Hospital, Melbourne, with the diagnosis of VGAMs and cardiac failure over the period 1996-2001 were identified. Only infants with VGAM or dural arteriovenous malformation (AVM) who presented at less than 1 month of age with cardiac failure were included. Each case was managed by at least one of the authors. This series includes two cases in which the diagnosis of VGAM was made before birth.
The case records of each infant were reviewed, and, where necessary, supplemental information was obtained from hospital notes and personal records of the authors. Specific information sought from these sources included: Eight infants were born at other centres and transported to our unit by a specialised neonatal transport service; one was delivered by caesarian section at our institution to minimise the effect of postnatal transport. Before transfer, basic management of severe cardiac failure secondary to VGAM consisted of mechanical ventilation and combination diuretic and inotropic support. A neonatal score, as proposed by Lasjaunias and ter Brugge, 10 was assigned on the basis of cardiac, respiratory, renal, hepatic, and cerebral dysfunction on arrival in our unit. Abnormal neurological events or seizures that occurred before sedation or neuromuscular blockade were scored appropriately. Seven infants, however, were electively intubated for transfer and were sedated or paralysed until after neurointervention. This prevented full neurological assessment, and these neonates were therefore assigned the highest (best) score in this section. Because the neurological component of the Lasjaunias score was difficult to assess, we also identified other prognostic indicators such as base excess or lactate.
After stabilisation, all infants were assessed by transthoracic Doppler echocardiography with colour flow mapping. One infant also had cardiac catheterisation to exclude hypoplastic left heart syndrome.
Transvenous embolisation through an existing femoral venous catheter or ultrasound guided transtorcular access was the intervention of choice in the first week of life despite the perceived increased risk of intracerebral bleeding, perforation, and morbidity with transvenous access. Transarterial embolisation was the preferred route of treatment for the second and subsequent interventions if cardiac failure persisted for 24-48 hours after the initial intervention. Table 1 summarises the clinical details of the cases. Mean (SD) gestational age was 39 (1.85) weeks and mean (SD) birth weight was 3382 (308) g. There was no evidence of hypoxaemia or birth asphyxia in seven of the nine infants. One infant (case 1) had an Apgar score of 2 at five minutes, requiring bag and mask ventilation for three minutes. Another (case 3) was flaccid and cyanosed at delivery, requiring intubation. All nine neonates subsequently presented with cardiomegaly, tachycardia, and tachypnoea consistent with high output cardiac failure on day 1. Initial stabilisation for transfer to our unit included elective intubation and ventilation. Two neonates (cases 3 and 4) rapidly progressed to MOF with hepatic dysfunction, disseminated intravascular coagulation, and respiratory failure. Seizures were present at diagnosis in one neonate (case 3), but none presented with intracranial haemorrhage or hydrocephalus. Three of the nine had serum lactate levels of 2.5-5 mmol/l (associated with 27% mortality in previous papers), 14 and six had serum lactate levels greater than 5 mmol/l (associated with 57% mortality).
RESULTS

Perinatal data
Neuroimaging
Choroidal VGAMs were diagnosed in eight patients, with one infant (case 6) having a dural AVM with aneurysmal Cardiac failure related to vein of Galen malformation F145
www.archdischild.com group.bmj.com on June 28, 2017 -Published by http://fn.bmj.com/ Downloaded from dilatation of the vein of Galen. Transcranial ultrasound with colour Doppler was used to quantify flow velocity and size of the aneurysm and to provide a baseline for subsequent follow up. Magnetic resonance imaging to exclude pre-existing cerebral injury and to characterise the anatomy was performed on day 1 unless fetal magnetic resonance imaging had been performed. Brain parenchyma was normal before intervention in seven of the nine neonates (table 1). All VGAMs were classified as choroidal or Yasargil type 3, 15 as would be expected in perinatal presentation with cardiac symptoms.
Echocardiography
Transthoracic echocardiography showed right ventricular enlargement with tricuspid insufficiency and raised pulmonary arterial pressure and normal left ventricular function in seven of the nine neonates. Reversal of flow during diastole was shown in the proximal descending thoracic aorta in seven of the nine cases. A patent ductus arteriosus with right to left shunting was present in seven cases. Suprasystemic pulmonary arterial pressure (calculated from tricuspid regurgitant jet) was present in five of the nine neonates. One neonate (case 4) also had cardiac catheterisation to exclude hypoplastic left heart syndrome before diagnosis of VGAM. In this case, right atrial and left and right ventricular end diastolic pressures were considerably raised. Right ventricular and pulmonary arterial pressures were suprasystemic compared with the measured left ventricular pressures. One infant has partial anomalous pulmonary venous drainage to the superior vena cava (sinus venosus), which has not yet been corrected.
Electrocardiography
Evidence of right ventricular hypertrophy was seen in six of the nine patients and combined ventricular hypertrophy in two patients (table 2) . Five of nine patients had unequivocal evidence of myocardial ischaemia before embolisation. 16 One infant (case 7) developed complete heart block (with a heart rate of 80 beats/min) during embolisation requiring emergency epicardial pacing.
Treatment of cardiac failure
Five of the nine neonates were initially stabilised with dopamine infusions and two with dobutamine infusions (table 2) . One patient (case 5) developed supraventricular tachycardia to a rate of 240 beats/min, necessitating cessation of high dose dopamine and adrenaline infusions. Systemic perfusion in this case abruptly improved in response to low dose dopamine in combination with sodium nitroprusside. From case 3 onwards, cardiac failure unresponsive to dopamine or dobutamine (up to a dose of 10 µg/kg/min) was treated with a combination of β adrenergic agonists and a vasodilator. The inotrope of choice was dopamine with either sodium nitroprusside (1-5 µg/kg/min) or glyceryl trinitrate (1-5 µg/kg/min). In three cases, direct acting arterial vasodilators in combination with β adrenergic agents yielded the most sustained improvement in systemic perfusion. In the final two patients in the series (cases 8 and 9), cardiac failure was treated solely with a phosphodiesterase inhibitor (milrinone 0.4-0.75 µg/kg/min).
The response to medical treatment was assessed by serial transthoracic echocardiography. Improved systemic perfusion was shown by increases in forward flow relative to reverse flow in the descending aorta and reduction in right to left ductal shunting. Inhaled nitric oxide was used in two neonates with severe pulmonary arterial hypertension but with limited effect on measured and calculated pulmonary arterial pressures.
All patients undergoing endovascular treatment in the first week of life were treated because of worsening cardiac failure despite maximal medical treatment. In unstable neonates transvenous embolisation using a femoral or ultrasound guided transtorcular approach was the primary intervention. This occurred between days 1 and 4 in the eight cases of refractory cardiac failure (12 procedures within first week of life, median age at first procedure 3 days). The only patient with cardiac failure not treated with endovascular treatment in the first week was managed medically until 6 months of age, when a series of three transarterial treatments were performed. This patient had severe stenosis of the main venous outflow from the VGAM, which would have decreased blood flow across the aneurysm and thus reduced the high output cardiac failure.
Hospital course
Of the eight patients treated in the first week of life for intractable cardiac failure, one was well controlled with the first treatment, one died during the initial treatment, and staged embolisation was required in six others at one, three, and four days after the initial treatment (table 3) . The five surviving neonates with cardiac failure required repeat endovascular treatment to treat recurrent cardiac or respiratory failure. Presentation was either failure to wean from mechanical ventilation or respiratory failure after extubation. Eight neonates with severe cardiac failure showed an immediate increase in systemic systolic and mean arterial blood pressure of 30-50% after coiling, but this was not maintained (table 2) . Clinically the hyperdynamic circulation persisted for a significant length of time despite reduction in AVM flow.
Outcome
One neonate in intractable cardiac failure (case 3) developed MOF with cardiac failure, respiratory failure, renal and hepatic dysfunction, and coagulopathy. She failed to respond to infusion of adrenaline (epinephrine) or noradrenaline (norepinephrine). Progressive failure to oxygenate in the presence of suprasystemic pulmonary arterial pressures was not reversed by nitric oxide (NO) to a maximum of 80 ppm. Emergency transvenous embolisation was complicated by severe unresponsive right heart failure and asystolic cardiac arrest during the procedure. In one other infant who died, treatment was discontinued at day 24 after computed tomography (CT) showed diffuse hypoxic-ischaemic cerebral injury and cortical laminar necrosis. This injury may have occurred during a pulmonary hypertensive crisis before the first endovascular treatment. One neonate developed extensive progressive encephaloleucomalacia after the fourth endovascular treatment consistent with cerebral ischaemia. This occurred despite resolution of cardiac failure and reduction in aneurysmal flow, suggesting a continuing steal phenomenon. Onset of sustained uncontrolled epilepsy led to withdrawal of treatment. Two of the neonates who died had transtorcular approaches to the VGAM. Five patients have no evidence of developmental delay or heart failure, and one awaits delayed clinical assessment. Mild developmental delay is present in the other survivor (case 4) at 36 months of age (table 3) . Imaging showed significant enlargement of cerebrospinal fluid spaces, parenchymal calcifications, and hypodensity consistent with venous hypertension and ischaemia. A ventriculoperitoneal shunt was performed for persistent hydrocephalus followed by surgical clipping of the remaining anterior cerebral artery supply.
Final angiograms showed complete (three) or near complete (three) angiographic obliteration in the six survivors. Follow up CT scans at 12-24 months were normal in five of the six survivors. The child with mild developmental delay has a small right temporoparietal infarct on CT scan.
Our policy on follow up imaging of these patients depends on the degree of occlusion achieved at embolisation. After discharge, infants are followed at three monthly intervals by the treating neonatologists until 12 months of age. Endovascular treatment sessions are arranged every three to six months depending on the clinical status and response to prior embolisation. At 6 months of age, follow up angiography is performed. If persistent high flow through the AVM is found, repeat transarterial embolisation is performed at the same session. A repeat angiogram at 12 months is indicated if less than complete occlusion is achieved at the six month angiogram. 13 
DISCUSSION
Without interventional neuroradiology and embolisation, the prognosis is poor for neonates whose primary presentation is early severe cardiac failure secondary to VGAM. Severe heart failure rapidly progresses to MOF and death. 17 It has been suggested that VGAM related cardiac failure presenting in the neonatal period with MOF is associated with a high rate of cerebral infarction and thus poor prognosis for long term neurodevelopmental outcome. 11 12 On this basis, endovascular treatment has been withheld in such babies. In this series, intervention was not withheld in neonates solely on the basis of severe cardiac failure. In our opinion, unless the excess flow through the AVM is reduced by early neurointervention and aggressive management of cardiac failure, severe cerebral injury occurs. This cohort of patients had significant risk of mortality associated with the VGAM. If assessed by Lasjaunias scores, only one neonate in this series would have been offered neurointervention before 5 months of age. Despite this, our results (five without neurological impairment, one moderate impairment, and three deaths) are similar to recent series, 1 4 18 19 in which selected neonates were treated after medical stabilisation for up to three months before the first intervention. The improved survival reported here may be due to our aggressive approach to early endovascular intervention as well as the management of cardiac failure used.
Cardiac failure associated with VGAM is unique. In utero cardiac failure secondary to VGAM is rare 20 21 because the low resistance of the cerebral AVM is balanced by the low resistance uteroplacental unit, allowing perfusion of the peripheries. With loss of the placenta at birth, up to 70% of cardiac output is directed to the cerebral circulation. Pulmonary arterial pressures remain raised, and the ductus arteriosus remains open, directing right ventricular output through the patent ductus arteriosus and into the descending aorta. 6 22 The right ventricle becomes distended and noncompliant because of the chronic pressure load. Subsequent right to left shunting at atrial and ductal levels causes arterial hypoxaemia and increases the likelihood of ventricular failure. The left ventricle is hyperkinetic with a shortening fraction greater than 40%. Biventricular failure may coexist with a supranormal shortening fraction. A normal shortening fraction therefore represents severe biventricular failure. 10 A large shunt through the VGAM occurs during diastole. This is suggested by diastolic retrograde filling of carotid arteries and reversal of flow in the descending aorta (steal phenomenon) at catheterisation, as well as differences in inferior and superior caval oxygen saturations. [22] [23] [24] The increased diastolic flow to the VGAM reduces coronary blood flow and, in combination with increased ventricular pressure, reduces subendocardial perfusion. This may produce myocardial ischaemia and potentially exacerbate right heart failure. Right ventricular pressure loading and ventricular septal interaction lead to low normal cardiac output. 22 25 Severe heart failure associated with VGAM appears to be more severe than heart failure associated with intracardiac anomalies that place a volume load on the right ventricle. It has been suggested that this is because the volume load is obligatory and continues despite increases in pulmonary artery resistance. 16 As a result, stabilisation of neonates before neurointervention or neurosurgery is difficult and the cardiac failure is often resistant to treatment.
The use of β adrenergic agents (dobutamine, dopamine, or adrenaline) in this setting often worsens cardiac output. 6 8 Improvements in contractility are not substantial because of the right ventricular dilatation and ventricular septal interdependence. Shortening of diastolic coronary filling time induced by tachycardia also worsens diastolic dysfunction. Elecrtocardiographic findings of myocardial ischaemia and pathological findings of subendocardial ischaemia suggest that subendocardial ischaemia contributes to the deterioration of ventricular function. 16 In our series, high dose β agonists were associated with significant adverse physiological events (including extreme tachyarrhythmias and transient ST-T wave changes consistent with ischaemia) and clinical deterioration. In contrast, low dose dopamine in combination with vasodilator treatment produced considerable improvement in systemic perfusion and reduction in metabolic acidosis.
The use of systemic arterial vasodilators or phosphodiesterase inhibitors has not previously been reported in neonates with VGAM who fail to respond to conventional inotropic support. Their use was based on the pathophysiology of an extracardiac, intracranial, low resistance circuit. Although total systemic vascular resistance is reduced with intracranial AVMs, extracranial systemic vascular resistance is raised. 22 26 Any intervention that reduces the extracranial systemic vascular resistance is likely to improve systemic perfusion and acidosis. 27 A case report of two neonates with severe cardiac failure secondary to VGAM receiving prostaglandin E1 supports this theory, as they sustained temporary increases in oxygenation and systemic perfusion. 26 Short term treatment with milrinone has not been reported in vein of Galen or other extracardiac AVMs, but phosphodiesterase inhibitors have been shown to improve indices of cardiac output in low cardiac output states after cardiac surgery. In the critically ill, milrinone improves systolic and diastolic function, produces systemic and pulmonary vasodilatation, and matches coronary arterial supply and demand. 28 Nitroprusside and nitroglycerine also improve systemic output by decreasing systemic vascular resistance in an analogous way to the effect of a low resistance placental bed. 2 29 In contrast, the two neonates in our series with the most severe cardiac failure did not respond to inhaled nitric oxide alone, as would be expected with persistent pulmonary hypertension. 8 The excessive cerebral blood flow in VGAMs adversely affects neurological outcome in a number of ways. 4 9 30 Raised cerebral venous pressure adversely affects regional cerebral blood flow, whereas periventricular leucomalacia is a result of a watershed phenomenon secondary to intracerebral arterial steal. Arterial vasodilators (especially nitroprusside, glyceryl trinitrate, and milrinone) used to treat severe cardiac failure have a role in reducing neurological injury before, during, and after surgery. 31 They play a significant role in stabilisation before intervention. During surgery, they offset rapid changes in systemic vascular resistance induced by coil occlusion of feeding vessels of the AVM. 32 Both ischaemia/reperfusion vascular injury and transmission of abrupt changes in perfusion through a pressure passive circulation are important in pathogenesis of germinal matrix haemorrhage. 33 After surgery, they may reduce the incidence of cerebral hyperaemia secondary to normal pressure breakthrough syndrome. 19 Prevention of hypertension during and after AVM embolisation also theoretically reduces the incidence of AVM nidus rupture secondary to increased intravascular pressure proximal to the site of occlusion or rerouting of blood flow and pressure away from the AVM. 9 34 35 Conclusion Severe neonatal cardiac failure secondary to VGAM is not an absolute contraindication to interventional neuroradiology provided that expert neonatal intensive care, anaesthesia, and interventional neuroradiology are available. It is our opinion that reproducing the balance of systemic vasodilatation seen in fetal life by appropriate low dose inotropic support and peripheral vasodilatation improves cardiac output. Phosphodiesterase inhibitors such as milrinone may be ideal for treatment of cardiac failure in patients with VGAM, especially those with reversal of flow in the descending aorta. Rapid progression to MOF despite aggressive medical treatment continues to be a contraindication to intervention because of poor neurological outcome. 
